



Published in final edited form as:

Clin Cancer Res. 2014 June 15; 20(12): 3358. doi:10.1158/1078-0432.CCR-14-1118.

Retraction: Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition

The article titled “Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition,” which was published in the September 15, 2010, issue of *Clinical Cancer Research* (1), is being retracted at the request of Pfizer, one of the study sponsors, following its investigation into the data from Study 1002, which was a phase II study designed to examine figitumumab, a humanized antibody to insulin growth factor I receptor, in combination with chemotherapy in non–small cell lung cancer.

While conducting database close-out activities, Pfizer became aware that the final data from Study 1002 differed from the results that had been previously reported. The primary efficacy results from the study were published in the *Journal of Clinical Oncology (JCO)* in May 2009, and the results of certain biomarker analyses performed in connection with it were published in the *British Journal of Cancer (BJC)* in January 2011 (2, 3). Pfizer provided both journals with new data, and both journals have retracted the affected articles.

These concerns, in combination with the issues that led to the retractions of the figitumumab articles published in *JCO* and *BJC*, have led Pfizer to conclude that the reported results from the figitumumab study are unreliable. Thus, Pfizer has requested a retraction of this article. A copy of this notice was sent to the authors prior to publication.

References

1. Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, et al. Molecular analysis of non–small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. *Clin Cancer Res.* 2010; 16:4654–65. [PubMed: 20670944]
2. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al. Phase II study of the anti–insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. *J Clin Oncol.* 2009; 27:2516–22. [PubMed: 19380445]
3. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. *Br J Cancer.* 2011; 104:68–74. [PubMed: 21102589]